Bristol Myers Squibb reports Phase 3 PFS advantage for ZENBEXUST plus daratumumab and dexamethasone

Bristol Myers Squibb said ZENBEXUST (iberdomide) in combination with daratumumab and dexamethasone (ZDd) demonstrated superior progression-free survival versus standard of care in Phase 3 for relapsed and refractory multiple myeloma.